To assess whether AMPK can modulate the motility and migration of cancer cells, we undertook a scratch assay with BT474, A549, MDA-MB-231 and MDA-MB-435S cells treated with either AMPK activator A769662 or its inhibitor Compound C. In keeping with a failure to induce mesenchymal marker expression in epithelial cell lines, AMPK activation failed to alter migration of BT474 cells (Fig. 2A and Fig. S2A). This evidence concerns the gene PRKAA2 and cancer.